Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) shares saw unusually-strong trading volume on Monday. Approximately 3,150 shares changed hands during mid-day trading, an increase of 34% from the average daily volume of 2,357 shares. The stock last traded at $37.00 and had previously closed at $35.38.
Analyst Ratings Changes
Several equities research analysts have recently weighed in on the stock. Zacks Research upgraded shares of Zealand Pharma A/S from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 12th. Barclays downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 8th. Wells Fargo & Company restated an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday, August 13th. Finally, Jefferies Financial Group lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold”.
View Our Latest Report on Zealand Pharma A/S
Zealand Pharma A/S Trading Up 6.9%
The company has a current ratio of 13.98, a quick ratio of 13.98 and a debt-to-equity ratio of 0.02. The stock has a market cap of $2.65 billion, a PE ratio of 6.14 and a beta of 0.99. The business has a 50 day moving average of $39.51 and a 200-day moving average of $47.26.
Zealand Pharma A/S Company Profile
Zealand Pharma A/S is a biotechnology company headquartered in Copenhagen, Denmark. Founded in 1998, it discovers and develops peptide-based medicines, with a focus on metabolic diseases and rare conditions.
The company’s portfolio has included Zegalogue (dasiglucagon), an injectable treatment approved in the United States for severe hypoglycemia in people with diabetes. Zealand also develops investigational medicines for areas such as obesity, liver disease and rare gastrointestinal disorders, and works with pharmaceutical partners to advance and commercialize selected programs.
Zealand Pharma serves international markets through its development and commercial partnerships.
Further Reading
- Five stocks we like better than Zealand Pharma A/S
- America’s Rare Earth Clock Is Running Out, But the Bottleneck Isn’t Where You Think
- Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength Remains
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
